EW · Edwards Lifesciences Corp
$91.60
-0.96 (-1.04%)
At close · Aug 14
Market Cap
$52.80B
Shares
576.40M
Edwards Lifesciences Corp Earnings Call Transcripts
Every quarterly earnings call for Edwards Lifesciences Corp (EW) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲0.7%
$1.32B
$343.50M
'22 Q3
22-10-27
▼67.7%
$429.90M
$398.40M
'22 Q4
23-01-31
▼8.9%
$1.22B
$340.50M
'23 Q1
23-04-26
▼6.9%
$1.28B
$307.10M
'23 Q2
23-07-26
▼5.7%
$1.24B
$384.90M
'23 Q3
23-10-25
▲194.6%
$1.27B
$369.90M
'23 Q4
24-02-06
▲8.9%
$1.33B
$351.90M
'24 Q1
24-04-25
▲7.1%
$1.37B
$366.30M
'24 Q2
24-07-24
▲8.9%
$1.35B
$3.07B
'24 Q3
24-10-24
▲9.4%
$1.39B
$385.60M
'24 Q4
25-02-11
▲6.2%
$1.41B
$358.00M
'25 Q1
25-04-23
▲11.9%
$1.53B
$333.20M
'25 Q2
25-07-24
▲14.7%
$1.55B
$291.10M
'25 Q3
25-10-30
▲13.3%
$1.57B
$91.20M
'25 Q4
26-02-10
▲16.7%
$1.65B
$380.70M
'26 Q1
26-04-23
LATEST
▲13.6%
$1.74B
$241.90M
'26 Q2
26-07-23
Earnings call
FY26 · Q2
2026-07-23
Q2 2026 Edwards Lifesciences Earnings Conference Call
Confident tone
TAVR franchise and Sapien platform
PROGRESS trial readout
TMTT (Pascal, Evoque, SAPIEN M3) momentum
Revenue
$1.74B
▲ 13.6% YoY Diluted EPS
$0.42
▼ 25% YoY Gross margin
77.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-04-23
Edwards Lifesciences Corp Q1 FY2026 Earnings Call
Confident tone
TAVR growth and market momentum
TMTT (mitral and tricuspid) portfolio
Surgical structural heart
Revenue
$1.65B
▲ 16.7% YoY Diluted EPS
$0.66
▲ 8.2% YoY Gross margin
78.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-10
Edwards Lifesciences to Present at the Barclays Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-10
Edwards Lifesciences Corp Q4 FY2025 Earnings Call
Confident tone
TAVR Growth Momentum and Durability Data
Early TAVR and Asymptomatic Indication
TMTT Portfolio Expansion
Revenue
$1.57B*
▲ 13.3% YoY Gross margin
78.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Edwards Lifesciences Corp Q3 FY2025 Earnings Call
Confident tone
TAVR franchise growth and clinical evidence
TMTT (Mitral and Tricuspid) portfolio expansion
R&D discipline and margin expansion
Revenue
$1.55B
▲ 14.7% YoY Diluted EPS
$0.50
▼ 90.3% YoY Gross margin
77.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-24
Edwards Lifesciences Corp Q2 FY2025 Earnings Call
Confident tone
TAVR growth and SAPIEN platform
TMTT (mitral/tricuspid) franchise leadership
TAVR leadership transition
Revenue
$1.53B
▲ 11.9% YoY Diluted EPS
$0.56
▼ 8.2% YoY Gross margin
77.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-23
Edwards Lifesciences Corp Q1 FY2025 Earnings Call
Confident tone
TMTT momentum and product approvals
Tariffs and financial guidance
TAVR growth and early TAVR expansion
Revenue
$1.41B
▲ 6.2% YoY Diluted EPS
$0.61
▲ 5.2% YoY Gross margin
78.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-11
Edwards Lifesciences Corp Q4 FY2024 Earnings Call
Confident tone
TMTT (mitral and tricuspid) momentum
TAVR growth and early TAVR catalyst
2025 financial guidance and outlook
Revenue
$1.39B
▲ 9.4% YoY Diluted EPS
$0.65
▲ 6.6% YoY Gross margin
78.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-24
Edwards Lifesciences Corp Q3 FY2024 Earnings Call
Confident tone
TAVR performance and outlook
TMTT growth (PASCAL, EVOQUE, SAPIEN M3)
Portfolio reshaping and Critical Care divestiture
Revenue
$1.35B
▲ 8.9% YoY Diluted EPS
$5.13
▲ 714.3% YoY Gross margin
80.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-24
Edwards Lifesciences Corp Q2 FY2024 Earnings Call
Cautious tone
TAVR sales shortfall and US hospital workflow pressure
TMTT growth and product launches
JenaValve and Endotronix acquisitions
Revenue
$1.37B
▲ 7.1% YoY Diluted EPS
$0.61
▲ 22% YoY Gross margin
79.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-25
Edwards Lifesciences Corp Q1 FY2024 Earnings Call
Confident tone
TAVR growth and SAPIEN platform
TMTT (mitral and tricuspid) growth
Critical Care spin-off
Revenue
$1.33B
▲ 8.9% YoY Diluted EPS
$0.58
▲ 3.6% YoY Gross margin
78.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-06
Edwards Lifesciences Corp Q4 FY2023 Earnings Call
Confident tone
TAVR growth and leadership
TMTT portfolio expansion
EVOQUE FDA approval and launch
Revenue
$1.27B
▲ 194.6% YoY Diluted EPS
$0.61
Gross margin
80.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-25
Edwards Lifesciences Corp Q3 FY2023 Earnings Call
Revenue
$1.24B
▼ 5.7% YoY Diluted EPS
$0.63
▲ 14.5% YoY Gross margin
79.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-26
Edwards Lifesciences Corp Q2 FY2023 Earnings Call
Revenue
$1.28B
▼ 6.9% YoY Diluted EPS
$0.50
▼ 23.1% YoY Gross margin
80.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-26
Edwards Lifesciences Corp Q1 FY2023 Earnings Call
Revenue
$1.22B
▼ 8.9% YoY Diluted EPS
$0.56
▼ 5.1% YoY Gross margin
81.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-31
Edwards Lifesciences Corp Q4 FY2022 Earnings Call
Revenue
$429.90M*
▼ 67.7% YoY Gross margin
123.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-27
Edwards Lifesciences Corp Q3 FY2022 Earnings Call
Revenue
$1.32B
▲ 0.7% YoY Diluted EPS
$0.55
▲ 1.9% YoY Gross margin
80.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-28
Edwards Lifesciences Corp Q2 FY2022 Earnings Call
Revenue
$1.37B
▼ 0.2% YoY Diluted EPS
$0.65
▼ 16.7% YoY Gross margin
80.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-26
Edwards Lifesciences Corp Q1 FY2022 Earnings Call
Revenue
$1.34B
▲ 10.2% YoY Diluted EPS
$0.59
▲ 9.3% YoY Gross margin
77.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-26
Edwards Lifesciences Corp Q4 FY2021 Earnings Call
Revenue
$1.33B*
▲ 11.6% YoY Gross margin
76.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-27
Edwards Lifesciences Corp Q3 FY2021 Earnings Call
Revenue
$1.31B
▲ 14.8% YoY Diluted EPS
$0.54
▲ 3.8% YoY Gross margin
76.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Edwards Lifesciences Corp Q2 FY2021 Earnings Call
Revenue
$1.38B
▲ 48.8% YoY Diluted EPS
$0.78
Gross margin
75.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-20
Edwards Lifesciences Corp Q1 FY2021 Earnings Call
Revenue
$1.22B
▲ 7.8% YoY Diluted EPS
$0.54
▲ 10.2% YoY Gross margin
75.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-27
Edwards Lifesciences Corp Q4 FY2020 Earnings Call
Revenue
$1.19B
▲ 1.5% YoY Diluted EPS
$0.49
▲ 11.4% YoY Gross margin
75.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-21
Edwards Lifesciences Corp Q3 FY2020 Earnings Call
Revenue
$1.14B
▲ 4.3% YoY Diluted EPS
$0.52
▲ 20.9% YoY Gross margin
75.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-23
Edwards Lifesciences Corp Q2 FY2020 Earnings Call
Revenue
$925.00M
▼ 14.9% YoY Diluted EPS
$-0.20
▼ 152.6% YoY Gross margin
74.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-23
Edwards Lifesciences Corp Q1 FY2020 Earnings Call
Revenue
$1.13B
▲ 13.7% YoY Diluted EPS
$0.49
▲ 25.6% YoY Gross margin
76.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-30
Edwards Lifesciences Corp Q4 FY2019 Earnings Call
Revenue
$1.17B
▲ 20.1% YoY Diluted EPS
$0.44
▲ 4300% YoY Gross margin
75.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
1099800
CUSIP
28176E108
13F (30d)
1164 filings
1132 filers
Visit website
Investor relations